Literature DB >> 9861560

A prognostic score for postherpetic neuralgia in ambulatory patients.

W Meister1, A Neiss, G Gross, H W Doerr, W Höbel, J P Malin, J von Essen, B Y Reimann, C Witke, P Wutzler.   

Abstract

The main objective was to develop a scoring system for easy use by the physician in daily clinical practice in deciding the appropriate treatment for his herpes zoster patient. Data from 635 patients who did not receive antiviral therapy were included in this analysis. Of these, 131 developed postherpetic neuralgia (PHN). Of the 29 variables tested univariately in this study, 15 showed a significant correlation with the incidence of PHN, but only six proved to contribute to the overall predictive power in the multivariate approach. Using two independent approaches, the model showed a very satisfactory performance in the validation sample. Patients without acute pain rarely developed PHN. In those with acute pain, being female, being over 50 years of age, having more than 50 lesions, having lesions of a hemorrhagic nature, having cranial or sacral localisation of the rash or having pain in the prodromal phase proved to be significant, multivariate factors. An easy-to-use scoring system used in a risk graph is proposed. These data should be useful in the individual treatment decision as well as in the design and analysis of therapeutic trials in herpes zoster.

Entities:  

Mesh:

Year:  1998        PMID: 9861560     DOI: 10.1007/BF02770836

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   7.455


  14 in total

1.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

2.  Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany.

Authors:  W Meister; A Neiss; G Gross; H Doerr; W Höbel; J Malin; J von Essen; B Reimann; C Witke; P Wutzler
Journal:  Intervirology       Date:  1998       Impact factor: 1.763

Review 3.  NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention.

Authors:  S E Straus; J M Ostrove; G Inchauspé; J M Felser; A Freifeld; K D Croen; M H Sawyer
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

Review 4.  Postherpetic neuralgia--pathogenesis, treatment, and prevention.

Authors:  R G Kost; S E Straus
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

5.  Risk factors for postherpetic neuralgia.

Authors:  P W Choo; K Galil; J G Donahue; A M Walker; D Spiegelman; R Platt
Journal:  Arch Intern Med       Date:  1997-06-09

6.  The cost of treatment for post-herpetic neuralgia in the UK.

Authors:  L Davies; L Cossins; D Bowsher; M Drummond
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 7.  Post-herpetic neuralgia in older patients. Incidence and optimal treatment.

Authors:  D Bowsher
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

8.  Herpes zoster with postherpetic neuralgia--persisting pain and frustration.

Authors:  D H Gilden
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

9.  Postherpetic neuralgia.

Authors:  R E Hope-Simpson
Journal:  J R Coll Gen Pract       Date:  1975-08

10.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

View more
  10 in total

Review 1.  [Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics].

Authors:  Miriam Wittek; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Klin (Munich)       Date:  2010-05-26

2.  Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Authors:  Timo Vesikari; Roland Hardt; Hans C Rümke; Giancarlo Icardi; Jordi Montero; Stéphane Thomas; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin Immunother       Date:  2013-01-14       Impact factor: 3.452

3.  Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.

Authors:  Robert Arnou; Anne Fiquet; Stéphane Thomas; Christine Sadorge
Journal:  Hum Vaccin       Date:  2011-10-01

4.  [Diagnostics and management of herpes zoster ophthalmicus].

Authors:  R N Werner; N-I Steinhorst; A Nast; U Pleyer
Journal:  Ophthalmologe       Date:  2017-10       Impact factor: 1.059

Review 5.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

Review 6.  Postherpetic neuralgia: from preclinical models to the clinic.

Authors:  Ada Delaney; Lesley A Colvin; Marie T Fallon; Robert G Dalziel; Rory Mitchell; Susan M Fleetwood-Walker
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 7.  A systematic review and meta-analysis of risk factors for postherpetic neuralgia.

Authors:  Harriet J Forbes; Sara L Thomas; Liam Smeeth; Tim Clayton; Ruth Farmer; Krishnan Bhaskaran; Sinéad M Langan
Journal:  Pain       Date:  2016-01       Impact factor: 7.926

Review 8.  Systematic review of incidence and complications of herpes zoster: towards a global perspective.

Authors:  Kosuke Kawai; Berhanu G Gebremeskel; Camilo J Acosta
Journal:  BMJ Open       Date:  2014-06-10       Impact factor: 2.692

9.  Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort.

Authors:  Mahrrouz Caputo; Johannes Horn; André Karch; Manas K Akmatov; Heiko Becher; Bettina Braun; Hermann Brenner; Stefanie Castell; Beate Fischer; Guido Giani; Kathrin Günther; Barbara Hoffmann; Karl-Heinz Jöckel; Thomas Keil; Birgit Klüppelholz; Lilian Krist; Michael F Leitzmann; Wolfgang Lieb; Jakob Linseisen; Christa Meisinger; Susanne Moebus; Nadia Obi; Tobias Pischon; Sabine Schipf; Börge Schmidt; Claudia Sievers; Astrid Steinbrecher; Henry Völzke; Rafael Mikolajczyk
Journal:  BMC Infect Dis       Date:  2019-01-30       Impact factor: 3.090

10.  Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  Hermann Einsele; Hartmut Bertz; Jörg Beyer; Michael G Kiehl; Volker Runde; Hans-Jochen Kolb; Ernst Holler; Robert Beck; Rainer Schwerdfeger; Ulrike Schumacher; Holger Hebart; Hans Martin; Joachim Kienast; Andrew J Ullmann; Georg Maschmeyer; William Krüger; Dietger Niederwieser; Hartmut Link; Christian A Schmidt; Helmut Oettle; Thomas Klingebiel
Journal:  Ann Hematol       Date:  2003-09-10       Impact factor: 3.673

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.